Gilteritinib for relapsed acute myeloid leukaemia with flt3 mutation during the COVID-19 pandemic: real world experience from the UK national health service
Authors
Othman, J.Afzal, U.
Amofa, R.
Austin, M. J.
Bashford, A.
Belsham, E.
Byrne, J.
Coats, T.
Dang, R.
Dennis, Michael
Dhawan, S.
Elliot, Johnathon
Francis, S.
Gallipoli, P.
Hodgson, K.
Kallmeyer, C.
Jain, M.
Katsomitrou, V.
Khan, A.
Khwaja, A.
Kolade, S.
Krishnamurthy, P.
Latif, A.
Laurie, J.
Lim, M.
Loke, C. T.
Manson, C.
Marshall, S. R.
Mobashwera, B.
Munisamy, S.
Murray, D.
Murthy, V.
Palanicawandar, R.
Saunders, J.
Smith, M.
Smith, K.
Sternberg, A.
Taussig, D.
Taylor, T.
Freeman, S. D.
Craddock, C.
Dillon, R.
Affiliation
Department of Medical and Molecular Genetics, King's College, London, United KingdomIssue Date
2021
Metadata
Show full item recordCitation
Othman J, Afzal U, Amofa R, Austin MJ, Bashford A, Belsham E, et al. Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398804278.Journal
BloodDOI
10.1182/blood-2021-150169Additional Links
https://dx.doi.org/10.1182/blood-2021-150169Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-150169